Naslov: | Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy : subgroup safety analysis from the phase 3b CompLEEment-1 trial |
---|
Avtorji: | ID Borštnar, Simona (Avtor) ID Palacova, Marketa (Avtor) ID Łacko, Aleksandra (Avtor) ID Timcheva, Constanta (Avtor) ID Gal-Yam, Einav Nili (Avtor) ID Papazisis, Konstantinos (Avtor) ID Beniak, Juraj (Avtor) ID Kudela, Pavol (Avtor) ID Rubovszky, Gábor (Avtor) |
Datoteke: | PDF - Predstavitvena datoteka, prenos (462,13 KB) MD5: B4B999D036C16F5550970C551FC25443
|
---|
Jezik: | Angleški jezik |
---|
Tipologija: | 1.01 - Izvirni znanstveni članek |
---|
Organizacija: | OI - Onkološki inštitut Ljubljana
|
---|
Povzetek: | The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2- advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demonstrated superior overall survival in premenopausal patients with HR+/HER2- ABC (MONALEESA-7). The multinational, phase 3b, CompLEEment-1 trial, which assessed the safety and efficacy of ribociclib plus letrozole in a broader population of patients who have not received prior endocrine therapy for advanced disease, is the largest phase 3 clinical trial to date to evaluate the safety and efficacy of a CDK4/6 inhibitor. We report a subanalysis of data from patients (N = 339) enrolled in the central and south European countries of the SERCE (Southern Europe, RUC, Central Europe) cluster of CompLEEment-1. Patients and methods: Men and women of any menopausal status with HR+/HER2- ABC received once-daily oral ribociclib 600 mg (3-weeks on/1-week-off), plus letrozole 2.5 mg continuously. Men/premenopausal women also received a GnRH-agonist. The primary outcome was the number of patients with adverse events (AEs) over a timeframe of approximately 36 months. Time-to-progression, overall response rate, and clinical benefit rate were also measured. Results: Safety results in the SERCE subgroup were consistent with those in the pivotal clinical trials of ribociclib in combination with endocrine therapy. Treatment-related AEs leading to dose adjustments/interruption occurred in 63.1% of patients but led to treatment discontinuation in only 10.6%. The most common treatment-related AEs of grade ≥ 3 were neutropenia and transaminase elevations. There were no fatal treatment-related events. Conclusions: These findings from the SERCE subgroup support the safety and manageable tolerability of ribociclib in a broad range of patients with HR+/HER2- ABC more representative of patients in real-world clinical practice. |
---|
Ključne besede: | CDK4/6 inhibitor, HER2−, HR+, advanced breast cancer, ribociclib |
---|
Status publikacije: | Objavljeno |
---|
Verzija publikacije: | Objavljena publikacija |
---|
Datum objave: | 01.01.2022 |
---|
Založnik: | Association of Radiology and Oncology |
---|
Leto izida: | 2022 |
---|
Št. strani: | str. 238-247 |
---|
Številčenje: | Vol. 56, no. 2 |
---|
Izvor: | Ljubljana |
---|
PID: | 20.500.12556/DiRROS-19763 |
---|
UDK: | 618.19-006 |
---|
ISSN pri članku: | 1318-2099 |
---|
DOI: | 10.2478/raon-2022-0020 |
---|
COBISS.SI-ID: | 108184835 |
---|
Avtorske pravice: | by Authors |
---|
Datum objave v DiRROS: | 24.07.2024 |
---|
Število ogledov: | 305 |
---|
Število prenosov: | 251 |
---|
Metapodatki: | |
---|
:
|
Kopiraj citat |
---|
| | | Objavi na: | |
---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |